Description     Claims     Drawing  

WO9217188A   [0014] 
WO0155221A   [0016] 
US20080051567A   [0017] 

Multiple myeloma outlook   [0004] 
Heparanase: busy at the cell surface   [0009] 
Syndecan-1: a dynamic regulator of the myeloma microenvironment   [0009] 
Regulation, function and clinical significance of heparanase in cancer metastasis and angiogenesis   [0009] 
Non-anticoagulant heparins and inhibition of cancer   [0009] 
Heparanase: structure, biological functions, and inhibition by heparin-derived mimetics of heparan sulfate   [0009] 
Modulation of the Heparanase-inhibiting Activity of Heparin through Selective Desulfation, Graded N-Acetylation, and Glycol Splitting   [0009] 
Structure and active domains of heparin   [0010] 
Structure and biological interactions of heparin and heparan sulfate   [0010] 
Heparin as an anticancer therapeutic   [0011] 
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy   [0011] 
Glycol-splitting as a device for modulating inhibition of growth factors and heparanase inhibition by heparin and heparin derivative   [0012]  [0013] 
Merck index   [0015] 
World J. Gastroenterol   [0015] 
World J. Gastroenterol   [0015] 
Bioorg. Med Chem   [0015] 
Toward a biotechnological heparin through combined chemical and enzymatic modification of the Escherichia coli K5 polysaccharide   [0022] 
Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol   [0042] 
Generation of anti-factor Xa active, 3-O-sulfated glucosamine-rich sequences by controlled desulfation of oversulfated heparins   [0042] 
Novel regio- and stereo-selective modifications of heparin in alkaline solution. Nuclear magnetic resonance spectroscopic evidence   [0043] 
Base-catalyzed conversion of the α-L-iduronic acid 2-sulfate unit of heparin into a unit of α-L-galacturonic acid, and related reactions   [0043] 
Undersulfated and Glycol-Split Heparins Endowed with Antiangiogenic Activity   [0043] 
High-performance liquid chromatographic/mass spectrometric studies on the susceptibility of heparin specie to cleavage by heparanase   [0044] 
Development of a colorimetric assay for heparanase activity suitable for kinetic analysis and inhibitor screening   [0044] 
Current Protocols in Cell Biology   [0044] 
The syndecan-1 heparan sulfate proteoglycan is a viable target for myeloma therapy   [0045]